Data as of Aug 29
| +0.29 / +0.63%|
The 28 analysts offering 12-month price forecasts for Novo Nordisk A/S have a median target of 49.70, with a high estimate of 64.53 and a low estimate of 33.83. The median estimate represents a +8.13% increase from the last price of 45.96.
The current consensus among 29 polled investment analysts is to Buy stock in Novo Nordisk A/S. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.